2007
DOI: 10.1016/j.jmb.2007.05.065
|View full text |Cite
|
Sign up to set email alerts
|

Spackling the Crack: Stabilizing Human Fibroblast Growth Factor-1 by Targeting the N and C terminus β-Strand Interactions

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

1
39
0

Year Published

2008
2008
2018
2018

Publication Types

Select...
6
1

Relationship

4
3

Authors

Journals

citations
Cited by 29 publications
(40 citation statements)
references
References 53 publications
1
39
0
Order By: Relevance
“…One must decouple the effects of the two to control folding (9) and design fast folding scaffolds. These scaffolds can then be programmed for specific function (10).…”
mentioning
confidence: 99%
“…One must decouple the effects of the two to control folding (9) and design fast folding scaffolds. These scaffolds can then be programmed for specific function (10).…”
mentioning
confidence: 99%
“…Mutations were combined with a screen for protein folding, stability, and solubility, and were retained if they were neutral or improved upon such properties. Maximum use was made of previously published data (26)(27)(28)(29)(30)(31)(32)(33)(34) as well as sequence analysis to identify useful symmetric mutations in FGF-1. A summary of the application of specific transforms in pursuing a symmetric deconstruction of FGF-1 follows.…”
Section: Methodsmentioning
confidence: 99%
“…The SYM7ΔΔ mutant was initially modified by the inclusion of two previously described stabilizing point mutations (Lys12Val and Pro134Val) (30) to produce the SYM9ΔΔ mutant. These mutations are located in the adjacent first and last β-strands of the β-barrel of the architecture, respectively, and represent a "discontinuous" β-turn within the threefold architecture.…”
Section: Methodsmentioning
confidence: 99%
“…The mutant proteins were developed via a series of protein stability and folding studies with FGF-1 and were identified experimentally as having enhanced stability, functional half-life, or mitogenic activity. 6,[22][23][24][25][26][27][28] The previously described thermodynamic stability properties and available in vitro mitogenic activity as well as in vivo half-life values are summarized in Table I. The rationale used for the selection of mutants examined in this study is based on the results in Table I (WT FGF-1 and mutants are labeled A-L).…”
Section: Selection Of Fgf-1 Mutantsmentioning
confidence: 99%
“…29 Alternatively, the P134V/C117V (E) mutant has enhanced stability (DDG ¼ À9.3 kJ/mol) yet exhibits similar mitogenic activity in comparison to WT FGF-1 (A). Other examples include K12V/C117V (F) and K12V/C117V/ P134V (H) which are stabilizing mutations that, in the absence of heparin, achieve similar mitogenic potency to that of WT formulated in the presence of heparin (mutants E, F, and H were designed to stabilize N-and C-termini b-strand interactions, a region of known structural weakness within FGF-1 24 ) The mutants C83T/C117V/K12V (D), C83T/ C117V/L44F/F132W (I), and oxidized A66C (G) have eliminated one or more free thiols, in comparison to WT FGF-1 (A). These mutations substantially increase their in vitro functional half-life with varying effects on thermostability (by mutating exclusively at solvent-inaccessible positions, thereby limiting immunogenic potential 6,27 ).…”
Section: Selection Of Fgf-1 Mutantsmentioning
confidence: 99%